Enzo Biochem, Inc. news

   Watch this stock
Showing stories 1 - 9 of about 9   

Articles published

ENZ 4.31 +0.17 (4.11%)
price chart
ENZO BIOCHEM REPORTS ACROSS THE BOARD SECOND QUARTER 2014 ...
NEW YORK, NY, March 11, 2014-- Enzo Biochem Inc. (NYSE:ENZ) today reported across-the-board improved results for the fiscal second quarter ended January 31, 2014 as compared to the corresponding year-ago period.
Healthcare new highs: Retrophin Inc (NASDAQ:RTRX), Enzo Biochem (NYSE ...
On March 11, Enzo Biochem, Inc.(NYSE:ENZ) reported across-the-board improved results for the fiscal second quarter ended January 31, 2014 as compared to the corresponding year-ago period.
The Thorny Problem of Patentable Eligible Subject Matter: An Introduction
The Federal Circuit specifically mentioned these Guidelines in Enzo Biochem, Inc. v. Gen-Probe Inc. stating that �The PTO has issued Guidelines governing its internal practice for addressing that issue.
Related articles »  
Traders Recap - B2Gold Corp (NYSEMKT:BTG), DFC Global Corp (NASDAQ ...
Las Vegas, NV - April 03, 2014 - (TechSonian) - B2Gold Corp (NYSEMKT:BTG) engages in the exploration and development of mineral properties in Nicaragua, Colombia, Namibia, and Uruguay.
Related articles »  
Traders Recap - Neuralstem, Inc. (NYSE MKT: CUR), Synta Pharmaceuticals ...
Neuralstem, Inc. (NYSEMKT:CUR) gained +4.48% percent with 86.22 million shares crossing the floor of the Exchange. The typical daily volume of this stock is about 1.65 million shares.
Related articles »